cisplatin,gemcitabine,nivolumab
bms
['mibc', 'nivolumab', ' aca ', 'hcrn,gu,16-257', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', ' gem ', 'nivo', 'bladder']
#gu23 stellar presents co-primary endpoints from #hcrn: gem cis, + nivo w/ selective bladder sparing in pts w #mibc: ccr of 43% 
Senior Executive & Chief GU Cancers @DanaFarber; Prof Medicine @HarvardMed; 2021 Giants of Cancer Award ⚽ lover; 🚲@PanMass, seen on @msnbc @cnn @TODAYshow